Congratulations to the following individuals for obtaining extramural funding from federal, state, and/or independent sources between August 1 and October 31, 2019!

NOTE: The Office of the Dean provided the information below to The Pulse. If there is any information that was inadvertently omitted, please contact the editor (dflock@lsuhsc.edu) and a correction will be printed in the next issue of The Pulse.

National Institutes of Health (R01):

  • Jennifer Lentz, PhD (Neuroscience Center of Excellence)
    • “Antisense Therapy for the Treatment of Visual Loss in Usher Syndrome”
  • Bolin Liu, MD (Department of Genetics)
    • “ErbB3-miRNA Axis in Tumor Metastasis of erbB2-positive Breast Cancer”
  • Qiang Shen, MD, PhD (Department of Genetics)
    • “Targeting Glucose Metabolism with HJC0152 for Treating Metastatic Breast Cancer”

National Institutes of Health (UH3):

  • Patricia Molina, MD, PhD (Alcohol and Drug Abuse Center of Excellence)
    • “Alcohol and Metabolic Comorbidities in PLWHA; Evidence-Driven Interventions”

National Institutes of Health (T32):

  • Patricia Molina, MD, PhD (Alcohol and Drug Abuse Center of Excellence)
    • “Biomedical Alcohol Research Training Program”

National Institutes of Health (UG1):

  • Augusto Ochoa, MD (Stanley S. Scott Cancer Center)
    • “Gulf South Minority/Underserved Clinical Trials Network (Gulf South M/U CTN)”

National Institutes of Health (Clinical Trials):

  • Stephanie Taylor, MD (Department of Medicine, Section of Infectious Diseases)
    • “A Phase 4 Comparative Trial of Benzathine Penicillin G 2.4 Million Units Administered as a Single Dose versus Three Successive Weekly Doses for Treatment of Early Syphilis in Subjects With or Without HIV Infection” 

Pharmaceutical and Company Grants:

  • Matthew Lammi, MD (Department of Pulmonary/Critical Care and Allergy/Immunology)
    • PPD Development
    • “A Phase 2, Double-Blind, Placebo-Controlled Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of RVT-1201 in Subjects with Pulmonary Arterial Hypertension”
  • Aaron Mammoser, MD (Department of Neurosurgery)
    • Cordgenics LLC
    • “Cordgenics CG01-GBM: Standard Chemotherapy Versus Chemotherapy Chosed By Cancer Stem Cell Chemosensitivity Testing in the Management of Patients with Recurrent Glioblastoma Multiforme”
  • Aaron Mammoser, MD (Department of Neurosurgery)
    • Global Coalition for Adaptive Research
    • “A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE)” 
  • Stephanie Taylor, MD (Department of Medicine, Section of Infectious Diseases)
    • NIH/BARTA GlaxoSmithKline
    • “A Phase III, Randomized, Multi-Center, Open-Label Study in Adolescent and Adult Participants Comparing the Efficacy and Safety of Gepotidacin to Ceftriaxone Plus Azithromycin in the Treatment of Uncomplicated Urogenital Gonorrhea caused by Neisseria gonorrhoeae”
  • Stephanie Taylor, MD (Department of Medicine, Section of Infectious Diseases)
    • Global Antibiotic Resistance Research and Development Partnership (GARDP)
    • “A Multi-center, Randomized, Open-label, Non-inferiority Trial to Evaluate the Efficacy and Safety of a Single, Oral Dose of Zoliflodacin Compared to a Combination of a Single Intramuscular Dose of Ceftriaxone and a Single Oral Dose of Azithromycin in the Treatment of Patients with UncompIicated Gonorrhoea”
  • Alan Velander, MD (Department of Neurosurgery)
    • Biogen
    • “A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BllB093 with Brain Contusion”

Academic and University Awards:

  • David Lefer, PhD (Cardiovascular Center of Excellence)
    • Tulane University
    • “Insulin-Like Growth Factor-1 and Atherosclerosis”